All the Active Ingredient Drugs
Tyrosine Kinase Inhibitor. Erlotinib 25 mg, 100 mg, 150 mg. FC Tab 100,150 mg
Non-Small Cell Lung Cancer: daily dose of Erlotinib is 150 mg taken at least
one hour bef. or two hours after food.
Pancreatic cancer: daily dose of Erlotinib is 100 mg taken at least one hour bef. or two hours after food, in combin. with gemcitabine.
NSCLC (non-small cell lung cancer):
* First line tmt in pts with locally adv. or metast. NSCLC if cancer cells express mutations in EGFR.
* Maint. tmt. in pts with locally adv. or metast. NSCLC if cancer cells express mutations in EGFR and the dis. remains largely unchanged after initial chemother. trmt.
* Tmt of pts with locally adv. or metast. NSCLC if at least one prev. chemother. tmt. was unsuccessful in stopping the dis.
Pancreatic cancer:
* First line tmt in pts with locally adv., unresectable or metast. pancreatic cancer, in combin. with gemcitabine.
C/I: Hypersens.
Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg. TABS: 30 x 100 mg, 150 mg. Non-small
cell lung cancer: 150 mg 1 x dly
without food. Pancreat. cancer: 100 mg
dly without food in comb. with
gemcitabine.
First-line tmt. locally advanced/metastat.
non-small cell lung cancer (NSCLC) with
EGFR activat. mutats. Tmt. locally.
advanced/metastat. NSCLC aft. fail. of at
least one prior chemother. reg. Monother.
for maint. tmt. pts with locally advanc./
metastat. non-small cell lung cancer
whose disease not progress. aft. 4 cycles of
platinum-based first-line chemother. In
comb. with gemcitabine for first-line tmt.
with locally advanced, unresect./
metastat. pancreat. cancer.
C/I: Hypersens.
Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg. TABS: 30 x 100 mg, 150 mg. Non-small
cell lung cancer: 150 mg 1 x dly
without food. Pancreat. cancer: 100 mg
dly without food in comb. with
gemcitabine.
First-line tmt. locally advanced/metastat.
non-small cell lung cancer (NSCLC) with
EGFR activat. mutats. Tmt. locally.
advanced/metastat. NSCLC aft. fail. of at
least one prior chemother. reg. Monother.
for maint. tmt. pts with locally advanc./
metastat. non-small cell lung cancer
whose disease not progress. aft. 4 cycles of
platinum-based first-line chemother. In
comb. with gemcitabine for first-line tmt.
with locally advanced, unresect./
metastat. pancreat. cancer.
C/I: Hypersens. to erlotinib or excips.
